ArticleHuman vaccines & immunotherapeutics2018
One year immunogenicity and safety of subunit plague vaccine in Chinese healthy adults: An extended open-label study.
Article in Human vaccines & immunotherapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- Plagued by the Past, Pressed by the Present: A One Health Perspective onBiomedicines · 2025Review
- Silent Carriers: The Role of Rodents in the Emergence of Zoonotic Bacterial Threats.Pathogens (Basel, Switzerland) · 2025Review
- Novel Bivalent mRNA-LNP Vaccine for Highly Effective Protection against Pneumonic Plague.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nanolipoprotein particle (NLP) vaccine confers protection againstFrontiers in immunology · 2025Article
- Evaluation of human antibodies from vaccinated volunteers for protection againstMicrobiology spectrum · 2024Article
- A novel sORF gene mutant strain of Yersinia pestis vaccine EV76 offers enhanced safety and improved protection against plague.PLoS pathogens · 2024Article
- The efficacy, safety, and immunogenicity of plague vaccines: A systematic literature review.Current research in immunology · 2023Review
- The magnitude of the germinal center B cell and T follicular helper cell response predicts long-lasting antibody titers to plague vaccination.Frontiers in immunology · 2022Article
- Article
- Plague vaccines: new developments in an ongoing search.Applied microbiology and biotechnology · 2021Review
- Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis.PLoS neglected tropical diseases · 2019Article
- Plague vaccine: recent progress and prospects.NPJ vaccines · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo evaluate the one-year immunogenicity and safety of a subunit plague vaccine.
methodsIn the initial study, 240 healthy adults aged 18-55 years were administrated with 2 doses of 15 or 30 µg plague vaccines at day 0 and 28, respectively. In this extended follow-up study, we evaluated the immunogenicity and safety of the plague vaccine up to one year.
resultsFor antibody to envelope antigen faction 1 (F1) antigen, titers were up to new peaks at month 6, then declined slowly to month 12, but remained at higher levels than those at day 56. Geometric mean titers (GMTs) of F1 were significantly higher in 30 µg group than those in 15 µg group at month 6 and 12 (P < 0.0001 and P < 0.001). However, approximate 100% seroconversion rates of F1 antibodies were found in both 15 and 30 µg groups at the both time points. For antibody to recombinant virulence (rV) antigen, titers and seroconversion rates were decreased sharply at month 6 and continue to decrease at month 12. GMTs and seroconversion rates were not significantly different between the 15 and 30 µg groups, respectively. No serious adverse events (SAEs) related to vaccine occurred.
conclusionThe new plague vaccine (F1+rV) induced a robust immune response up to 12 months and showed a good safety profile in adults aged 18-55 years.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.